Document is current
Any future updates will be listed below
-
Authors
Nio, Kouki
Shimakami, Tetsuro
Terashima, Takeshi
Yanagi, Masahiro
Toyama, Tadashi
Koshikawa, Naohiko
Nakagawa, Masatoshi
Yoshida, Eisaku
Yoshimura, Toru
Seiki, Motoharu
Honda, Masao
Yamashita, Taro
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP23ck0106662h, JP23ck0106662h, JP23ck0106662h, JP23ck0106662h, JP23ck0106662h, JP23ck0106662h, JP23fk0210122)
Japan Society for the Promotion of Science (JP21H02900)
- License Information
-
More Information
Article History
Received: 25 December 2023
Accepted: 18 October 2024
First Online: 25 October 2024
Declarations
:
: NK, MN, EY, TY (Toru Yoshimura), and MS are inventors of the patented LG2m test and its technology has been licensed to Abbott Laboratories. MN, EY, and TY (Toru Yoshimura) are employees of Abbott Japan LLC and owe stock of Abott Laboratories which is parent company of Abott Japan. TY (Taro Yamashita) ad NK received a grant for the development of HCC diagnostic markers for chronic liver disease patients from Abbott Laboratories. All other authors declare no competing interests. The funders had no role in the study design, data collection, analysis and interpretation, decision to publish, or writing of the report.
: The study was conducted in accordance with the standards set by the Declaration of Helsinki and was approved by the institutional review board of the Graduate School of Medical Sciences, Kanazawa University.
: Patients consented in advance to the storage of their serum for future research, and we guaranteed the patients the opportunity to opt out of this research by posting and disclosing a summary of the study on our website ().
